$330M Oversubscribed: Ollin’s Faricimab Challenger Just Became the Most Funded Retinal Disease Bet of 2026
Ollin Biosciences closed an oversubscribed $330M Series B on June 24 to run global Phase 3 trials of OLN324...
Lilly’s $7.8B Centessa Bet Signals a New M&A Playbook: Buy the Mechanism, Not the Molecule
Lilly's $7.8B Centessa acquisition, approved by UK High Court on June 22, reveals Big Pharma's new M&A logic: own...
J&J’s MonumenTAL-3 Data Rewrites the Myeloma Playbook Before the Ink Dries on DPd
MonumenTAL-3 delivers 81.3% PFS at 24 months for talquetamab plus daratumumab, threatening DPd's grip on earlier RRMM treatment lines.
AbbVie’s Skyrizi Machine Is Writing Checks Its Oncology Pipeline Now Has to Cash
Skyrizi hit $4.48B in Q1 2026 revenue. AbbVie is deploying that cash into oncology—and the CLL14 nine-year data just...
Biogen’s Immunology Buying Spree Reveals a Strategy the Neurology Playbook Can No Longer Support
Biogen's $1B RayThera deal is its second major immunology acquisition in two years. A pipeline pivot this deliberate signals...
Adaptive Biotechnologies’ Split Isn’t a Retreat — It’s a Confession That One Company Can’t Serve Two Masters
Adaptive Biotechnologies separates its profitable $145M MRD diagnostics unit from its AI-driven TCR platform, betting two focused stories beat...
Sanofi’s Tzield Just Opened a Market That Didn’t Exist Last Week
Tzield's FDA approval for stage 3 type 1 diabetes creates a new disease-modifying therapy category for 2.1M U.S. patients...
Tzield’s Stage 3 Approval Signals the End of Insulin’s Monopoly on Type 1 Diabetes
Sanofi's Tzield just won FDA approval for stage 3 T1D, threatening insulin's 68% grip on a $28.6B market and...
Biotech’s Uncomfortable Adolescence: Capital Is Back, But the Industry Has Changed Permanently
Biotech VC hit $26B in 2024 as IPOs lagged and China licensing surged—here's what the recovery's structure reveals about...
Disc Medicine’s FDA Meeting Just Reset the Bitopertin Timeline: What the Street Should Actually Be Watching
After a Feb 2026 CRL rejection, Disc Medicine secured FDA alignment on a Phase 3 pathway for bitopertin in...